The FDA approval of pirtobrutinib for previously untreated CLL/SLL adds another targeted option to an already rapidly evolving frontline treatment landscape. Based on results from the phase 3 BRUIN CLL-313 trial, pirtobrutinib is now approved for adults with previously untreated CLL/SLL without del(17p). The key question is less whether pirtobrutinib is effective, and more where it fits among the increasingly crowded array of frontline therapies and how its use today may influence treatment options at relapse.

BRUIN CLL-313 randomized 282 patients with previously untreated CLL/SLL without del(17p) to pirtobrutinib or bendamustine plus rituximab (BR). With a median follow-up of approximately 28 months, median PFS was not reached with pirtobrutinib compared with 33.5 months with BR.

Pirtobrutinib reduced the risk of disease progression or death by 80% (HR, 0.20; 95% CI, 0.11-0.37; P<.0001), while overall response rates were 94% and 81%, respectively. The magnitude of the PFS benefit matters, especially because the comparator represents an older chemoimmunotherapy approach, not a modern targeted regimen commonly used in frontline practice. Thus, the trial provides strong evidence for pirtobrutinib’s efficacy but does not establish that it should replace contemporary BTK inhibitor (BTKi) or venetoclax-based approaches for all patients.

Dr. Marc Hoffman, Director of the Lymphoma Program at The University of Kansas Cancer Center, said: “The recent approval of pirtobrutinib in the frontline setting does not dramatically change treatment for the majority of patients but does offer an additional option to a select group of patients who may have very specific cardiovascular problems in addition to their CLL.”

His perspective underscores an important point about the current landscape: with multiple highly effective targeted therapies already available, the addition of pirtobrutinib is likely to matter most for selected patients and is not a universal change in frontline practice. Cardiovascular comorbidities, bleeding risk, concomitant medications, treatment duration preferences, and anticipated tolerability all may influence the choice among available regimens. 

Pirtobrutinib’s move into the frontline setting introduces an important sequencing consideration. Using pirtobrutinib earlier may provide effective disease control, but clinicians must also consider which therapies remain available when the disease eventually progresses.

Dr. Victor Yazbeck, Director of Lymphoid Malignancies at VCU Massey Comprehensive Cancer Center, characterized the current environment as an “embarrassment of riches,” with multiple highly effective frontline therapies and a growing challenge in matching each one to the right patient at the right point in the disease course.

That sequencing question is increasingly central to CLL management. For a patient who prioritizes a fixed-duration approach, a venetoclax-based regimen may remain attractive, while another patient may favor continuous BTK inhibition. 

Pirtobrutinib offers an additional option when disease biology, comorbidities, anticipated toxicity, or prior treatment considerations make it particularly appropriate.

“The FDA approval of pirtobrutinib, a non-covalent BTK inhibitor previously used in relapsed CLL/SLL, brings another effective treatment option to the frontline setting,” said Dr. Omar Alkharabsheh, a medical oncologist with Orlando Health Cancer Institute.

“For oncologists, this approval expands the ability to personalize treatment decisions based on a patient’s comorbidities, preferences, and treatment goals.” In practical terms, that personalization means incorporating pirtobrutinib into an individualized treatment discussion. The approval doesn’t replace established frontline strategies.

The approval’s implications also extend beyond the initial line of therapy. Because pirtobrutinib has shown activity after covalent BTK inhibitor exposure, earlier availability in the disease course raises questions about the optimal sequence of BTKi and other targeted therapies. This will become increasingly important as patients live longer and move through multiple lines of targeted treatment. The goal is not simply to maximize first-line PFS, but to develop a treatment sequence that provides durable disease control while preserving effective options for subsequent therapy.

This is particularly relevant as combination strategies involving pirtobrutinib continue to develop.

Dr. Hoffman highlighted the potential importance of pirtobrutinib, venetoclax, and rituximab (PVR) in previously treated patients, noting that “outcomes for PVR are incredibly favorable and practice-changing for patients with relapsed CLL.”

Emerging combination data could ultimately shape how clinicians view where pirtobrutinib provides the greatest value across the treatment continuum.

For now, the frontline approval of pirtobrutinib is best viewed as an expansion of the CLL/SLL treatment options, not a mandate to change therapy for every newly diagnosed patient requiring treatment.

The BRUIN CLL-313 results establish pirtobrutinib as an effective option, while its mechanism and tolerability profile may make it particularly useful for selected patients. The larger clinical challenge is integrating it with established regimens while accounting for patient preferences, comorbidities, disease biology, treatment duration, and future lines of therapy.

As Dr. Yazbeck noted, the field now has multiple highly effective frontline therapies; the next challenge is determining “which treatment is best for which patient and in what sequence.” Continued follow-up and clinical trials evaluating sequencing and novel combinations will be critical to answering that question.